Tragara in-licenses S*BIO's SB1317

S*BIO (Singapore) granted Tragara (San Diego, Calif.) an exclusive, worldwide license to develop and commercialize SB1317. The orally available inhibitor of FMS-like tyrosine kinase 3 ( FLT3) and cycl...